RA
BIOTU

Ramius Advisors’s Biotech Acquisition Company Unit BIOTU Stock Holding History

Ramius Advisors’s Portfolio BIOTU Stock Details BIOTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-33,687
Closed -$340K – 288
2021
Q2 		$340K Sell
33,687
-54,273
-62% -$544K 0.13% 102
2021
Q1 		$870K Buy
+87,960
New +$905K 0.23% 119

Other funds holding BIOTU

AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
CCFM
Cohen & Co Financial Management New York $18.3M AUM 73.48% 1-Year Est. Return
HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Ramius Advisors's BIOTU Position: Q3 2021 in Review

Ramius Advisors sold out of Biotech Acquisition Company Unit (BIOTU) in Q3 2021, closing a stake of 33,687 shares — an estimated $340K sold.

Ramius Advisors first reported a position in BIOTU in Q1 2021 and held it in 2 quarters. The position peaked at $870K in Q1 2021. 34 funds tracked by Wall St. Rank hold BIOTU as of Q3 2021.

  • Ramius Advisors reported no remaining Biotech Acquisition Company Unit position as of Q3 2021 after selling out during the quarter.
  • Ramius Advisors sold 33,687 Biotech Acquisition Company Unit shares in Q3 2021, an estimated $340K.
  • Ramius Advisors first reported a position in Biotech Acquisition Company Unit in Q1 2021 and held it in 2 quarters.
  • Ramius Advisors's Biotech Acquisition Company Unit position peaked at $870K in Q1 2021.
  • 34 funds tracked by Wall St. Rank held Biotech Acquisition Company Unit as of Q3 2021.

Based on Ramius Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.